Merck & Co., Inc. (NYSE:MRK) EVP David Maraldo Sells 18,706 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) EVP David Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $128.61 on Friday. The firm has a market capitalization of $317.64 billion, a P/E ratio of 102.89, a P/E/G ratio of 5.53 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock’s 50-day simple moving average is $123.98 and its two-hundred day simple moving average is $119.11. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Institutional Trading of Merck & Co., Inc.

A number of hedge funds have recently bought and sold shares of the company. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $31,000. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target for the company. Bank of America raised their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. BMO Capital Markets lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Finally, Guggenheim upped their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research report on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $134.56.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.